Single-cell Genome Sequencing Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 15.20 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Single-cell Genome Sequencing Market Analysis
The Single-cell Genome Sequencing Market is projected to register a CAGR of 15.2% during the forecast period 2022-2027.
The COVID-19 pandemic had a positive effect on the studied market. Various research studies have been published about the impact of COVID-19 on single-cell sequencing. For Instance, in September 2020, research published titled 'Single-cell landscape of Immunological Responses in Patients with COVID-19' stated that coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host immune response is not fully understood. When single-cell sequencing was performed, most cell types in patients with COVID-19 showed a strong interferon-α response and an overall acute inflammatory response. Such studies provide inside into the application of single-cell sequencing on COVID-19. Similarly, in February 2022, another research study titled 'Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+ Monocytes and Memory CD8+T Cells Involved in Severe COVID-19' stated that there was a major genetics-modulated immunological shift between mild and severe infection, including an elevated expression of genetics-risk genes, increase in inflammatory cytokines, and of functional immune cell subsets aggravating disease severity, which provides novel insights into parsing the host genetic determinants that influence peripheral immune cells in severe COVID-19. Hence, such studies provide insight into COVID-19 and thus increase the market growth in the future.
Factors such as increasing diseases, initiatives by key market players, and increased funding are expected to increase the market growth. Rising disease prevalence is also likely to boost the drug development processes in the region, ultimately leading to the studied market expansion owing to the benefits offered by the devices. For Instance, as per the article titled ' United States Tax Dollars Funded Every New Pharmaceutical in the Last Decade' published in September 2020 2.2 million published research related to the biological drugs or targets of which 21% acknowledged funding from National Institutes of Health (NIH) of more than than USD 230 Billion. Such funding in the biotechnology field increases the research and the usage of PCR devices (including single-cell sequencing), boosting the market's growth. The collaboration among the market players and research institutes for the research and development of new diagnostics and treatment methods with the help of the sequencing method is also boosting the market's growth. For Instance, in January 2020, Illumina and Israel-based Danyel Biotech reported that scientists at the Weizmann Institute of Science in Israel are now using Illumina's next-generation sequencing (NGS) technology. Weizmann has been a pioneer of single-cell genomics, and Illumina's technology will enable the Institute's researchers to continue advancing this fast-growing field of research. The newly-installed system also expands genomic research capacity within Israel. The institutes are using NovaSeq 6000 system to investigate how cells within the immune system interact with healthy tissue and tumor cells. Since the use of NovaSeq 6000 enables researchers to sequence the genome, epigenome, and transcriptome (RNA sequence), it is expected to drive the growth of the studied market. Thus, due to the abovementioned factors, the market is likely to grow in the future.
However, analytical challenges related to single-cell genome sequencing will hinder the market's growth.
Single-cell Genome Sequencing Market Trends
This section covers the major market trends shaping the Single Cell Genome Sequencing Market according to our research experts:
PCR Segment is Expected to Hold a Significant Market Share Over the Forecast Period
The PCR segment is expected to hold a significant share in the market over the forecast period.
Factors such as initiatives by key market players such as product launches and collaborations are expected to increase the market growth in the forecast period. The market segment's growth is boosted by the launch of products in the market. For instance, in June 2020, Stilla Technologies launched one of the world's first six-color digital PCR instruments named 'the six-color Prism'. This system can be used widely in oncology, infectious disease, gene therapy, disease monitoring, and food testing. Similarly, in July 2022 Bio-Rad launched CFX Opus Deepwell real-time PCR detection system. Bio-Rad's CFx Opus Deepwell Real-time PCR Detection system is designed to support research in developing nucleic acid detection assays.
Additionally, the market segment is boosted by the strategic collaboration among the players to strengthen the opposition worldwide. For instance, in October 2021, PerkinElmer and Honeycomb Biotechnologies announced the launch of the first-of-its-kind HIVE scRNAseq Solution for single-cell isolation and analysis. The HIVE solution leverages a portable, handheld device for the capture, storage, and RNA-Seq library preparation of a diverse range of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes, and neurons. The HIVE solution requires no specialized instrumentation and expands opportunities for laboratories pursuing basic, translational, clinical, and preclinical research.
Thus, owing to the abovementioned factors, the PCR segment of the market is expected to project considerable growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a dominant share in market over the forecast period.
Factors such as rising disease prevalence and product launches and expansions by key market players are expected to drive market growth in the region. According to Cancer Statistics 2021, published in the American Cancer Society Journal, an estimated 1.9 million new cancer cases are diagnosed and 608,570 cancer deaths in the United States, which will drive the market significantly. Similarly, according to data by Globocan 2020, the country's estimated number of new cancer cases in 2020 was 195,449. The number of cancer cases in the country is expected to increase during the forecast period, thus driving the market's growth.
Furthermore, launching new products based on single-cell sequencing will drive market growth significantly. For instance, in September 2020, Roche received United States Food and Drug Administration (FDA) approval for the Cobas HIV-1/HIV-2 Qualitative Test for use on the fully automated Cobas 6800/8800 Systems in the US. The test will help healthcare professionals confirm HIV diagnosis with a single test and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options. In October 2021, Takara Bio USA, Inc., a fully owned subsidiary of Takara Bio Inc., launched the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System. Scientists can collect full-length transcriptome data from over 1,500 single cells simultaneously using this automated single-cell RNA-seq technology from a wide range of sample types, including huge, delicate adult cardiomyocytes. Furthermore, in March 2020, to fight the COVID-19 public health problem, inference, a Cambridge-based company, announced the creation of a first-of-its-kind software resource that synthesizes disparate Single Cell RNA-sequencing (scRNA-seq) data sets. The library includes the nferX augmented intelligence technology, which enables machines to understand over 100 million unstructured biomedical papers and correlate emerging insights from scientific literature with deep biological signals at the single-cell level.
Thus, due to the such factors, the studied market is expected to grow significantly during the forecast period.
Single-cell Genome Sequencing Industry Overview
The market is partially fragmented and consists of several major players. Some companies currently dominating the market are Fluidigm Corporation, QIAGEN, Illumina, Inc., F. Hoffmann-La Roche Ltd., and ThermoFisher Scientific, Inc.
Single-cell Genome Sequencing Market Leaders
-
QIAGEN
-
Fluidigm Corporation
-
Illumina, Inc.
-
F. Hoffmann-La Roche Ltd.
-
ThermoFisher Scientific, Inc.
*Disclaimer: Major Players sorted in no particular order
Single-cell Genome Sequencing Market News
- In March 2022, Kaneka Corporation launched KANEKA RT-PCR Kit 'SARS-CoV-2 (Omicron/Delta) ver.2', a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), 'Stealth' Omicron (BA.2), and Delta variants of COVID-19.
- In March 2022, Sengenics announced the commercial launch of the i-Ome Protein Array Kit. The i-Ome Protein Array Kit contains slide-based, high-density protein microarrays comprising 1600+ immobilized, full-length, correctly folded human proteins.
Single-cell Genome Sequencing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High R&D Investments in the Single cell Genomics
- 4.2.2 Growing Number of SCG Centers and Core Facilities
-
4.3 Market Restraints
- 4.3.1 Analytical Challenges Related to Single-cell Genome Sequencing
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 Product
- 5.1.1 Instruments
- 5.1.2 Reagents
-
5.2 Technology
- 5.2.1 Sequencing
- 5.2.2 PCR
- 5.2.3 Microarray
- 5.2.4 Others
-
5.3 Application
- 5.3.1 Cancer
- 5.3.2 Immunology
- 5.3.3 Microbiology
- 5.3.4 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 10x Genomics
- 6.1.2 BD
- 6.1.3 BGI
- 6.1.4 Bio-Rad Laboratories, Inc.
- 6.1.5 F. Hoffmann-La Roche Ltd.
- 6.1.6 Fluidigm Corporation
- 6.1.7 Illumina, Inc.
- 6.1.8 Oxford Nanopore Technologies plc.
- 6.1.9 PacBio
- 6.1.10 QIAGEN
- 6.1.11 Takara Bio Inc
- 6.1.12 ThermoFisher Scientific, Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablitySingle-cell Genome Sequencing Industry Segmentation
According to the scope, single-cell genome sequencing involves isolating a single cell, performing whole-genome-amplification (WGA), constructing sequencing libraries, and then sequencing the DNA using a next-generation sequencer. The Single-cell Genome Sequencing Market is Segmented by Product (Instruments and Reagents), Technology (Sequencing, PCR, Microarray, and Others), Disease Area (Cancer, Immunology, Microbiology, and Others), End User (Biotechnology & Biopharmaceutical Companies, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| Product | Instruments | |
| Reagents | ||
| Technology | Sequencing | |
| PCR | ||
| Microarray | ||
| Others | ||
| Application | Cancer | |
| Immunology | ||
| Microbiology | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Single-cell Genome Sequencing Market Research FAQs
What is the current Global Single-cell Genome Sequencing Market size?
The Global Single-cell Genome Sequencing Market is projected to register a CAGR of 15.20% during the forecast period (2024-2029)
Who are the key players in Global Single-cell Genome Sequencing Market?
QIAGEN, Fluidigm Corporation, Illumina, Inc., F. Hoffmann-La Roche Ltd. and ThermoFisher Scientific, Inc. are the major companies operating in the Global Single-cell Genome Sequencing Market.
Which is the fastest growing region in Global Single-cell Genome Sequencing Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Single-cell Genome Sequencing Market?
In 2024, the North America accounts for the largest market share in Global Single-cell Genome Sequencing Market.
What years does this Global Single-cell Genome Sequencing Market cover?
The report covers the Global Single-cell Genome Sequencing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Single-cell Genome Sequencing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Genome Sequencing Industry Report
Statistics for the 2024 Genome Sequencing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Genome Sequencing analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
